HIGHLIGHTS
- who: Igor Tchivilev from the Igor Tchivilev1, Nageswara RMadamanchi1, Aleksandr E. Vendrov, Xi-Lin Niu, and Marschall S. Runge, From the Department of Medicine, Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina, The development of therapeutic strategies to inhibit reactive oxygen species (ROS)-mediated damage in blood vessels has been limited by a lack of specific targets for intervention. Targeting ROS-mediated events in the vessel wall is of interest, because ROS play important roles throughout atherogenesis. In early atherosclerosis, ROS stimulate vascular smooth muscle cell (VSMC) growth, whereas in late stages of . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.